BAY-474 is a novel and potent inhibitor of tyrosine-protein kinase c-Met, acting as a structural genomics consortium (SGC) epigenetics probe.

RON-IN-1 (AMG-1) is a novel, potent and cell-permeable inhibitor of RON, also acts by inhibiting c-Met.

AMG 458 (AMG-458) is a novel c-Met inhibitor with potential anticancer activity.

PF-04217903 (PF04217903) is an orally bioavailabe and ATP-competitive small-molecule inhibitor of the tyrosine kinase c-Met with potential antitumor activity.

BMS-754807 (BMS754807) is an orally bioavailable small molecule inhibitor of IGF-1R/InsR (growth factor 1 receptor/insulin receptor family kinases) with potential antineoplastic activity.

MK-8033 HCl is a novel, potent, selective, ATP competitive small-molecule, dual inhibitor of c-Met/Ron (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer.

PF-04217903 phenolsulfonate is a novel, highly potent and ATP-competitive inhibitor of c-Met kinase inhibitor with Ki of 4.8 nM for human c-Met and has antiangiogenic properties.

SU11274 (also called PKI-SU11274; PKI-SU-11274) is a novel, potent and selective Met inhibitor with potential antineoplastic activity.

Capmatinib HCl hydrate (INCB28060; INC-280) is a n FDA-approved, orally bioavailable, ATP-competitive inhibitor of c-MET (IC50 = 0.13 nM in a cell-free assay) with anticancer activity.

Capmatinib 2HCl (INCB28060; INC-280; Tabrecta), the dihydrochloride salt of Capmatinib, is an orally bioavailable and ATP-competitive inhibitor of c-MET approved by FDA on August 10, 2022 by the US FDA for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation leading to mesenchymal-epithelial transition (MET) exon 14 skipping, as detected […]